Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased ...

As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff ...

Get insights from Ligand Pharmaceuticals' Q2 2025 earnings—57% royalty revenue growth, raised guidance, and key partnerships driving long-term growth.

Ligand Pharmaceuticals (NASDAQ:LGND), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7 ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

Orchestra BioMed announced today that it completed strategic transactions and equity offerings worth an expected $111.2 ...

Research indicates that high-dose vitamin D improves bone health in very low birth weight preterm infants, highlighting its ...

ABCL-575’s predicted dosing schedule of every six months is enabled by a "human half-life of approximately 67 days," as ...

The company said it plans to develop its new Chai‑2 platform to design, from square one, completely new antibodies for ...

EyePoint Pharmaceuticals completed enrollment in the LUCIA trial, its second phase 3 trial of Duravyu in patients with wet ...

A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel ...